Rigel Pharmaceuticals, Inc.
(NASDAQ : RIGL)

( )
RIGL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.94%88.651.3%$803.98m
AMGNAmgen Inc.
-0.76%185.501.2%$628.99m
GILDGilead Sciences, Inc.
-2.14%65.550.9%$482.29m
BIIBBiogen Inc.
-4.17%321.171.3%$427.44m
ILMNIllumina, Inc.
-1.77%296.883.5%$311.35m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%418.622.6%$290.18m
VRTXVertex Pharmaceuticals Incorporated
-2.55%183.061.9%$253.58m
ALXNAlexion Pharmaceuticals, Inc.
-1.76%127.552.0%$219.68m
SRPTSarepta Therapeutics, Inc.
-2.87%136.5415.4%$152.33m
AAgilent Technologies, Inc.
-0.83%77.911.6%$150.84m
EXASExact Sciences Corporation
-0.42%83.2825.3%$132.28m
INCYIncyte Corporation
-0.49%83.332.5%$111.93m
ARRYArray BioPharma Inc.
-1.99%22.718.2%$108.01m
EXELExelixis, Inc.
-0.09%21.226.4%$82.07m
NBIXNeurocrine Biosciences, Inc.
-2.58%77.315.1%$77.22m

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. It focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its current product development programs include Fostamatinib Oral SYK Inhibitor and R348 Topical Ophthalmic JAK/SYK Inhibitor. The company was founded by Donald G. Payan, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.